Published in AIDS Weekly, February 27th, 1995
Protease inhibitors are designed to interfere with the function of an enzyme crucial to HIV replication. As currently available antiretroviral agents target a different viral enzyme, it is hoped that combination therapy with both types of drug will deliver a powerful two-pronged attack on HIV. Several protease inhibitors are already in Phase II clinical trials (see the accompanying article).
But data from one of these trials, together with laboratory studies, show that the human serum alpha-1 acid...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.